drug

World Data Ocean keeps drug in one place: 3 stories so far. The section currently leads with “Off-label testosterone use rises as female libido research lags”, “Leucovorin Use Increased After White House Autism Treatment Promotion”, and “Early Alzheimer’s Drug Data Shows Promise, Reveals Unexpected Nuance”. Off-label testosterone use is rising as demand for female libido treatments grows, yet the research remains insufficient. In fall 2025, the Trump administration promoted leucovorin for autism therapy without presenting new evidence, and pediatric dispensing of the drug rose in response. A Global Hub for Ocean Intelligence 4 World Data Ocean is a centralized digital platform where researchers, scientists, and ocean enthusiasts converge to… The list below is every drug story on World Data Ocean, newest first.

Off-label testosterone use rises as female libido research lags
Science News

Off-label testosterone use rises as female libido research lags

Off-label testosterone use is rising as demand for female libido treatments grows, yet the research remains insufficient. This imbalance between clinical practice and empirical evidence demands attention. Validated, peer-reviewed studies are essential to guide safe, effective care. For a broader perspective on how shifting research priorities affect scientific progress, see our related coverage: "AI and quantum gains shift focus from broader ocean science priorities."

Leucovorin Use Increased After White House Autism Treatment Promotion
Science News

Leucovorin Use Increased After White House Autism Treatment Promotion

In fall 2025, the Trump administration promoted leucovorin for autism therapy without presenting new evidence, and pediatric dispensing of the drug rose in response. That gap between claim and data is precisely where public trust in treatment guidance can erode. We track such intersections of policy and measurable health outcomes, much like our coverage in "Gate Delays Expose Critical Link in National Trade Flow." The takeaway is not about the drug itself, but about what happens when advocacy outpaces empirical validation. Understanding drives protection.

Early Alzheimer’s Drug Data Shows Promise, Reveals Unexpected Nuance
Science News

Early Alzheimer’s Drug Data Shows Promise, Reveals Unexpected Nuance

An experimental Alzheimer's drug has delivered something rare in this field: measurable progress with an unexpected complication. The compound lowered tau levels in the brain and slowed aspects of memory decline, yet the nuance in the data is as instructive as the headline. That kind of layered result is what real progress looks like. For readers tracking the broader picture, our coverage of lymphatic system intervention in an Alzheimer's model offers a complementary thread worth pulling.